pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 10·1 min read
save

Global Ebola preparedness fixated on one strain, leaving other species vulnerable

Aug 10, 2026·read at STAT ↗Negative

In an opinion piece, infectious-diseases physician Krutika Kuppalli and virologist Placide Mbala argue that the term "Ebola" masks several distinct virus species, each with different diagnostic and therapeutic needs.

They note that for most of the last decade global preparedness has centered on Zaire ebolavirus (EBOV), the strain behind the 2014-2016 West Africa epidemic, while other species received little attention.

The ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo, now the country’s largest Ebola epidemic and the second-largest ever recorded, exposes this narrow focus and underscores a critical gap in global health readiness.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: We prepared for Ebola — but not this Ebola”

read at STAT ↗
1,564 words · retrieved Aug 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Moderna, Inc.
drugs
Ebola Zaire vaccine7NVCov-2R2VEKLURY2remdesivir2
topics
Vaccine9Vaccines7Diagnostics Company6Infectious Disease2Monoclonal Antibody2Small MoleculemRNA TherapeuticmRNA Vaccine

related stories

  • Aug 10Opinion: We prepared for Ebola — but not this EbolaSTAT
  • 1d agoNovo workforce down 13,000BioSpace
  • Aug 5The main therapy used for children with autism faces changes under MedicaidSTAT
  • Jul 17Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesBioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech